FDA Generics Office Gets Third Director In Three Workdays; Uhl Brings Policy, Pharmacology Experience
This article was originally published in The Pink Sheet Daily
Executive Summary
A long-time FDA veteran who remains largely unknown to the generics industry, Kathleen Uhl replaces CDER Director Janet Woodcock as acting director of the Office of Generic Drugs effective March 19 following Gregory Geba’s March 15 departure from the generic office’s top post.
You may also be interested in...
FDA’s Office Of Generic Drugs Gets New Permanent Director And Oversight Designee
Iilun Murphy, a 15-year agency veteran, takes helm of OGD. Jacqueline Corrigan-Curay to assume oversight of the office and report to CDER director.
The Risk-Reward Of US FDA Leadership Running Offices Below Them
CBER’s Celia Witten is the latest senior executive to run an office within the center during a leadership transition, a move that can help achieve specific goals, but also create tension.
Generic Industry Once Again Must Get To Know New US FDA Office Director
Incoming Office of Generic Drugs Director Sally Choe is largely unfamiliar to industry, but potentially offers a new perspective.